NovaMedica is a new kind of pharmaceutical company. Our strategy is to search the world for important new approved products that will help improve the health care of Russians, in addition to the exciting line of pipeline products we will in-license from the portfolio companies of Domain Associates in which our shareholders choose to invest. We will bring these products to Russia and the CIS countries and then market them to Russian/CIS specialty physicians and health care providers better than anyone else. As part of our mission to be a leading provider in Russia and the CIS of innovative specialty pharma products and solutions that treat a range of therapeutic disorders, we will be developing this site over the coming months to provide Russian and CIS healthcare professionals with an assortment of educational and information resources.
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem (World Health Organization).
Please inform us of any adverse events that might be associated with our pharmaceutical products:
· via the hotline: +7 (800) 222-49-08
· by e-mail:
Pharmaceutical safety information is extremely important as it helps ensure that medicinal products are being used in an effective and safe manner.
06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
Optimising wet granulation manufacturing with advanced technologies
03 October 2024
First-in-class therapy approved for schizophrenia
03 October 2024
The Russian Ministry of Health proposed changes to essential drug lists
02 October 2024
WHO guidance aims to strengthen clinical trial ecosystem
02 October 2024